EMA Shifts Gear On Patient Feedback During Drug Review
Pilot To Focus On Orphan Medicines For Which CHMP Review Is Imminent
Executive Summary
The European Medicines Agency is exploring the feasibility and utility of contacting patients’ organizations for their input as soon as its medicines evaluation committee starts reviewing a new drug.